The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...

Three chemical structures with various rods and rings in multiple colors appear over a gray, bumpy background. An X-ray crystal structure of MK-8527 triphosphate (TP) bound to the complex of HIV ...

After hitting the mark in a phase 2 of its investigational islatravir paired with Gilead Sciences' lenacapivir, Merck & Co.'s islatravir is making further strides as a combination treatment with ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

The drugs, called NRTIs, have the potential to prevent a million cases of Alzheimer's every year, the researchers believe. UVA Health scientists are calling for clinical trials testing the potential ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...

Share on Pinterest New research suggests that HIV drugs may have a protective effect against Alzheimer’s. Willie B. Thomas/Getty Images Researchers at UVA Health have found that a class of HIV drugs ...

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...